Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

Non-small Cell Lung Cancer Clinical Trial

Official title:

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03633110
• Other study ID #: GEN-009-101
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: August 29, 2018
• Est. completion date: February 28, 2022

Study information

• Verified date: April 2022
• Source: Genocea Biosciences, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study, Genocea is evaluating an investigational, personalized adjuvanted vaccine, GEN-009, that is being developed for the treatment of patients with solid tumors. A proprietary tool developed by Genocea, called ATLAS™ (Antigen Lead Acquisition System) will be used to identify neoantigens in each patient's tumor that are recognized by their CD4 and/or CD8 T cells. ATLAS-identified neoantigens will then be incorporated into a patient's personalized vaccine in the form of synthetic long peptides (SLPs).

Description:

This first-in-human study of GEN-009 will be conducted in two parts in adult patients with cutaneous melanoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma, or renal cell carcinoma (Part B only). In Part A, the safety and immunogenicity of single-agent GEN-009 will be evaluated in patients with the above-noted tumor types who have completed treatment with curative intent for their disease (eg, surgical resection, neoadjuvant and/or adjuvant chemotherapy, and/or radiation therapy) and have no evidence of disease (NED) at the time of initiating vaccination with GEN-009. In Part B, up to 15 patients in each disease cohort will be enrolled and evaluated for safety, immunogenicity, and preliminary antitumor activity of GEN-009. Patients in Part B will receive GEN-009 at the schedule selected in Part A, in combination with a PD-1 inhibitor therapy (nivolumab or pembrolizumab) at the approved dose and schedule per the United States Package Insert (USPI). In addition, up to 15 patients who enroll in one of the Part B disease-specific cohorts but whose disease progresses during the screening period therapy may be enrolled into a separate relapsed/refractory disease cohort.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: February 28, 2022
• Est. primary completion date: December 8, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

General Inclusion Criteria:

• Diagnosis of 1 of the following tumor types:

1. Melanoma (cutaneous).

2. NSCLC.

3. SCCHN (oral, oropharyngeal, hypopharyngeal, or laryngeal).

4. Urothelial carcinoma.

5. Renal cell carcinoma (Part B only).

• Understand the study, be willing to comply with all study procedures and sign the informed consent

• Adequate tumor tissue available

• ECOG performance status of 0 or 1

• Negative pregnancy test (females of childbearing potential)

• Agree to use of contraception during the study until at least 90 days after final GEN-009 dose

• Adequate hematologic, liver, and kidney function

Part A-specific Inclusion:

• Have completed or will complete treatment for their disease with curative intent

• Have no evidence of disease

Part B-specific Inclusion:

• Receiving or will initiate treatment with nivolumab or pembrolizumab per disease as listed below:

1. NSCLC: Patients with metastatic non-squamous NSCLC beginning first-line pembrolizumab in combination with pemetrexed and platinum chemotherapy, or metastatic squamous NSCLC beginning first-line pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel

2. SCCHN: Patients beginning pembrolizumab with recurrent or metastatic SCCHN with disease progression on or after a platinum-based therapy, or beginning first-line pembrolizumab for recurrent or metastatic SCCHN if tumors express PD-L1 with a Combined Positive Score (CPS) = 1.

3. Cutaneous Melanoma: Patients with unresectable or metastatic cutaneous melanoma beginning nivolumab monotherapy or nivolumab in combination with ipilimumab.

4. Urothelial Carcinoma: Patients with locally advanced or metastatic urothelial carcinoma who are beginning pembrolizumab who:

1. Are not eligible for cisplatin-containing chemotherapy, and tumor is PD-L1 positive with CPS = 10, or are not eligible for any platinum-containing chemotherapy, OR

2. Have had disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

5. Renal Cell Carcinoma:

1. Patients with advanced RCC who have received prior anti-angiogenic therapy, and are beginning nivolumab monotherapy, OR

2. Untreated patients with intermediate or poor risk RCC based on the IMDC score who are beginning nivolumab in combination with ipilimumab.

• Disease assessment by CT or MRI

• Have at least 1 lesion that is measureable by RECIST 1.1

• Agree to a tumor biopsy 50 days after first GEN-009 vaccination

• Participants with hypothyroidism must be on thyroid replacement treatment

General Exclusion Criteria:

• Received a live vaccine = 28 days, or a non-live vaccine = 14 days, prior to the first dose of GEN-009

• Acute or chronic skin disorders that would interfere with injection

• Receiving immunosuppressive therapies or systemic corticosteroids. Note: Use of topical corticosteroids or inhaled corticosteroids is acceptable

• Allergy to the vaccine adjuvant Hiltonol (poly-ICLC)

• Active hepatitis B or hepatitis C infection

• HIV Positive

• History of clinically significant cardiac condition

• History of leptomeningeal carcinomatosis

• Had clinically active immune-mediated disease within 5 years

• Received a prior allogeneic stem cell transplant

• Has primary immune deficiency

• Received a prior solid organ transplant

• Has malignant disease, other than the tumor types being treated in this study

• Female patient who is pregnant, breastfeeding, or who plans to become pregnant from the signing of the informed consent until = 90 days from last dose of GEN-009

• Any condition that in the judgment of the PI would make the patient inappropriate for enrollment in the study

• Patient has received cytotoxic chemotherapy within 4 weeks of the first leukapheresis

Part A-specific Exclusion Criteria:

• Has received or requires more than 2 adjuvant or neoadjuvant regimens (other than surgical excisions) given with curative intent prior to first GEN-009 vaccination

• Has not recovered or stabilized from any clinically significant toxicity associated with any prior procedure or anticancer therapy

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Renal Cell
• Cutaneous Melanoma
• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Squamous Cell Carcinoma of Head and Neck
• Squamous Cell Carcinoma of the Head and Neck
• Urothelial Carcinoma

Intervention

Biological:
• GEN-009 Adjuvanted Vaccine
GEN-009 Adjuvanted Vaccine consists of GEN-009 Drug Product mixed with Hiltonol (poly-ICLC, adjuvant) and is administered by subcutaneous injection.

Drug:
• Nivolumab
Nivolumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.
• Pembrolizumab
Pembrolizumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.

Locations

Country	Name	City	State
United States	University of Colorado, Anschutz Cancer Pavilion	Aurora	Colorado
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	Karmanos Cancer Institute	Detroit	Michigan
United States	The University of Texas MD Anderson Cancer Center	Houston	Texas
United States	UC San Diego Moores Cancer Center	La Jolla	California
United States	University of Wisconsin Carbone Cancer Center	Madison	Wisconsin
United States	The Sarah Cannon Research Institute	Nashville	Tennessee
United States	Columbia University Medical Center - Herbert Irving Pavilion	New York	New York
United States	University of Nebraska Medical Center	Omaha	Nebraska
United States	Hospital of the University of Pennsylvania	Philadelphia	Pennsylvania
United States	John Wayne Cancer Institute - Providence Saint John's Health Center	Santa Monica	California

Sponsors (1)

Lead Sponsor	Collaborator
Genocea Biosciences, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Long-term clinical outcomes of Part A participants	Disease recurrence	1.5 years after first GEN-009 vaccination
Other	Additional cellular responses after vaccination with GEN-009	Cytokine secretion	1 year after first GEN-009 vaccination
Other	Phenotype of circulating immune cells after vaccination with GEN-009	Measured by flow cytometry	1 year after first GEN-009 vaccination
Other	Tumor-infiltrating T cells after vaccination with GEN-009	Will be examined in tumor biopsies	1 year after first GEN-009 vaccination
Primary	Incidence of Treatment-Emergent Adverse Events	Adverse events will be graded according to the NC Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0	1.5 years after first GEN-009 vaccination
Primary	T-cell responses to GEN-009 adjuvanted vaccine	Immunogenicity based on T-cell responses to GEN-009	1.5 years after first GEN-009 vaccination
Secondary	Antitumor activity of GEN-009 in Part B	Evaluation conducted based on RECIST v1.1 (and immune-related RECIST [irRECIST], where appropriate)	48 weeks after first GEN-009 vaccination

External Links

•   OPDIVO (nivolumab) United States Prescribing Information